UY35144A - Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca - Google Patents

Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca

Info

Publication number
UY35144A
UY35144A UY0001035144A UY35144A UY35144A UY 35144 A UY35144 A UY 35144A UY 0001035144 A UY0001035144 A UY 0001035144A UY 35144 A UY35144 A UY 35144A UY 35144 A UY35144 A UY 35144A
Authority
UY
Uruguay
Prior art keywords
bioconjugates
polypeptides
heart failure
apeline
mimetics
Prior art date
Application number
UY0001035144A
Other languages
English (en)
Spanish (es)
Inventor
Frédéric Zecri
Grosche Philipp
Yasoshima Kayo
Zhao Hongjuan
Yuan Jun
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY35144A publication Critical patent/UY35144A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
UY0001035144A 2012-11-20 2013-11-18 Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca UY35144A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728395P 2012-11-20 2012-11-20
US201361781397P 2013-03-14 2013-03-14
US201361858251P 2013-07-25 2013-07-25

Publications (1)

Publication Number Publication Date
UY35144A true UY35144A (es) 2014-06-30

Family

ID=49876968

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035144A UY35144A (es) 2012-11-20 2013-11-18 Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca

Country Status (9)

Country Link
US (1) US10005829B2 (https=)
EP (1) EP2922559B1 (https=)
JP (2) JP6444882B2 (https=)
CN (1) CN105007928B (https=)
AR (1) AR093559A1 (https=)
ES (1) ES2705323T3 (https=)
TW (1) TW201425339A (https=)
UY (1) UY35144A (https=)
WO (1) WO2014081702A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
JP6505691B2 (ja) 2013-07-25 2019-04-24 ノバルティス アーゲー 心不全治療用の環状アペリン誘導体
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3157942B1 (en) 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
WO2016102648A1 (en) * 2014-12-23 2016-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor
ES2930077T3 (es) * 2016-02-15 2022-12-07 Inst Nat Sante Rech Med Apelina para su uso en el tratamiento de la disfunción cognitiva posoperatoria
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3649146B1 (en) 2017-07-03 2024-06-26 The Governors of the University of Alberta Apelin peptides and uses thereof
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CN114269367A (zh) * 2019-08-15 2022-04-01 科巴公司 治疗性肽
CN114099642A (zh) * 2021-11-12 2022-03-01 南通大学 基因Apln在制备治疗与细胞成血管有关疾病药物中的应用
WO2026007693A1 (zh) * 2024-07-05 2026-01-08 浙江大学 Apelin-13多肽突变体

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
US5155100A (en) 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE59109151D1 (de) 1991-06-21 1999-10-14 Boehringer Ingelheim Pharma Verwendung von (s)(+)-2-äthoxy-4-[n-[1-(2-piperidino-phenyl)-3-methyl-1-butyl]aminocarbonylmethyl]-benzoesäure zur herstellung eines langzeitantidiabetikums
DE10199058I2 (de) 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
CA2128208C (en) 1992-11-17 2004-01-06 Ronald Godiska Novel seven transmembrane receptors
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW313568B (https=) 1994-12-20 1997-08-21 Hoffmann La Roche
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU1685499A (en) 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
AU5759399A (en) * 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
CA2346064A1 (en) 1998-10-05 2000-04-13 Takeda Chemical Industries, Ltd. Method for removing n-terminal methionine
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
US6521607B1 (en) 1999-09-23 2003-02-18 Pharmacia Corporation (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
DE60119714T2 (de) 2000-03-23 2006-09-07 Takeda Chemical Industries, Ltd. Peptidderivat
IL152081A0 (en) 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
WO2001090123A2 (en) 2000-05-23 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
JP3935487B2 (ja) 2001-07-16 2007-06-20 フーベルト・ケスター 捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
WO2003063892A1 (en) 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Use of apelin
TW200407310A (en) 2002-06-07 2004-05-16 Glaxo Group Ltd Compounds
EP1537114B8 (en) 2002-08-07 2007-10-03 Novartis AG Organic compounds as agents for the treatment of aldosterone mediated conditions
WO2004046145A1 (en) 2002-11-18 2004-06-03 Novartis Ag Imidazo[1, 5a]pyridine derivatives and methods for treating aldosterone mediated diseases
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
US20050152836A1 (en) 2003-05-22 2005-07-14 Euan Ashley Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
US7947280B2 (en) 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
EP1520861A1 (en) 2003-09-11 2005-04-06 Aventis Pharma Deutschland GmbH Test system for the identification of APJ receptor ligands
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
CN1997643A (zh) 2004-05-28 2007-07-11 斯皮德尔实验股份公司 杂环化合物及其作为醛固酮合酶抑制剂的应用
CA2568159A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
AR050251A1 (es) 2004-05-28 2006-10-11 Speedel Experimenta Ag Compuestos heterociclicos con nitrogeno heteroatomico y composicion farmaceutica en base al compuesto
CN101035756A (zh) 2004-06-17 2007-09-12 南卡罗来纳州医科大学研究发展基金会 非天然氨基酸
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
JP2008013436A (ja) 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
US20110097710A1 (en) 2004-10-26 2011-04-28 Macrae Calum A Methods for detecting atrial fibrillation and related conditions
WO2006076736A2 (en) 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US7736346B2 (en) 2005-10-18 2010-06-15 Biocardia, Inc. Bio-interventional therapeutic treatments for cardiovascular diseases
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
US20080031871A1 (en) 2006-02-21 2008-02-07 Allen Margaret L Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
EP2009080A4 (en) 2006-04-04 2010-05-26 Taiyo Nippon Sanso Corp METHOD OF REMOVING METHANE, METHANE PARATOR AND METHOD USE SYSTEM
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
US20090324610A1 (en) 2006-04-25 2009-12-31 Kyushu Univeristy, National University Corporation Gene associated with arteriosclerotic disease, and use thereof
WO2007128568A1 (en) 2006-05-10 2007-11-15 Novartis Ag Bicyclic derivatives as cetp inhibitors
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
JP2010501573A (ja) 2006-08-25 2010-01-21 ノバルティス アクチエンゲゼルシャフト アルドステロン合成酵素および／または１１−β−ヒドロキシラーゼおよび／またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体
EP2094680A2 (en) 2006-12-18 2009-09-02 Novartis AG Imidazoles as aldosterone synthase inhibitors
WO2008076860A1 (en) 2006-12-18 2008-06-26 Novartis Ag 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors
CN101578272A (zh) 2006-12-18 2009-11-11 诺瓦提斯公司 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途
PL2134720T3 (pl) 2007-03-29 2011-04-29 Novartis Ag Heterocykliczne spiro-związki
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
JP2010538071A (ja) 2007-09-07 2010-12-09 セラヴァンス， インコーポレーテッド 二重作用性降圧剤
US20100204113A1 (en) 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
WO2009033819A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2463282B1 (en) 2007-11-05 2013-08-07 Novartis AG 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
MX2010006063A (es) 2007-12-03 2010-07-01 Novartis Ag Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
US20110123534A1 (en) 2007-12-12 2011-05-26 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
EP2297113A1 (en) 2008-04-29 2011-03-23 Theravance, Inc. Dual-acting antihypertensive agents
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
BRPI0919932A8 (pt) 2008-10-24 2018-02-06 Novartis Ag Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína
CN102203117A (zh) * 2008-11-04 2011-09-28 安科治疗公司 Apj受体化合物
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
HRP20140371T1 (hr) 2009-05-15 2014-05-23 Novartis Ag Arilpiridini kao inhibitori sinteze aldosterona
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
EP2496243A2 (en) 2009-11-04 2012-09-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2457216C1 (ru) 2010-12-21 2012-07-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) Додекапептиды, обладающие кардиопротекторными свойствами
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013153049A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides as apelin inhibitors and uses thereof
TWI580771B (zh) 2012-07-25 2017-05-01 奈寇公司 以控制系統及演算法爲基礎之分析器之設計開發與實施
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
JP6505691B2 (ja) * 2013-07-25 2019-04-24 ノバルティス アーゲー 心不全治療用の環状アペリン誘導体
CN105705167A (zh) * 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
MX2016001020A (es) * 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
US9683018B2 (en) * 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure

Also Published As

Publication number Publication date
EP2922559A2 (en) 2015-09-30
JP2016501851A (ja) 2016-01-21
JP6444882B2 (ja) 2018-12-26
WO2014081702A4 (en) 2014-09-04
CN105007928B (zh) 2018-03-20
TW201425339A (zh) 2014-07-01
WO2014081702A3 (en) 2014-07-17
WO2014081702A2 (en) 2014-05-30
US20150284446A1 (en) 2015-10-08
CN105007928A (zh) 2015-10-28
JP2018172410A (ja) 2018-11-08
AR093559A1 (es) 2015-06-10
ES2705323T3 (es) 2019-03-22
US10005829B2 (en) 2018-06-26
EP2922559B1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
UY35144A (es) Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU20160013A7 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca
JO3380B1 (ar) مشابهات ابيلين اصطناعية لعلاج قصور القلب
EA201690282A1 (ru) Биоконъюгаты синтетических апелиновых полипептидов
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
PE20171328A1 (es) Conjugados de acidos grasos y apelina sintetica con mayor vida media
JP2017513944A5 (https=)
ECSP12011627A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st
AR096980A1 (es) Polipéptidos cíclicos para el tratamiento de insuficiencia cardiaca
TN2016000029A1 (en) Bioconjugates of synthetic apelin polypeptides
JP2017502089A5 (https=)
TH146851A (th) อะเพลินมิเมติกสังเคราะห์สำหรับการรักษาภาวะหัวใจล้มเหลว